ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.904,66
-0,08%
S&P 500
5.730,95
-0,25%
US Dollar vs BRL
5,4334
-0,09%
Bitcoin
65.625,27
0,68%
Brent Oil
71,715
1,08%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Personalis Inc (PSNL)

  7. Personalis Inc (PSNL) Notícias

PSNL

Personalis (PSNL)

Personalis Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PSNL
DataHoraFonteTítuloCódigoCompanhia
19/09/202418:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSNLPersonalis Inc
16/09/202410:00Business WireESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD TestNASDAQ:PSNLPersonalis Inc
12/09/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSNLPersonalis Inc
30/08/202417:43Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PSNLPersonalis Inc
22/08/202417:01Business WirePersonalis to Participate at Upcoming Investor ConferencesNASDAQ:PSNLPersonalis Inc
20/08/202417:27Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:PSNLPersonalis Inc
20/08/202417:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSNLPersonalis Inc
19/08/202417:05Business WirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSNLPersonalis Inc
16/08/202409:30Business WirePersonalis and Tempus Announce Expanded CollaborationNASDAQ:PSNLPersonalis Inc
07/08/202417:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSNLPersonalis Inc
07/08/202417:01Business WirePersonalis Reports Second Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
06/08/202417:05GlobeNewswire Inc.Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%NASDAQ:PSNLPersonalis Inc
31/07/202417:01Business WirePersonalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 ConferenceNASDAQ:PSNLPersonalis Inc
24/07/202417:01Business WirePersonalis to Announce Second Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
11/07/202410:00GlobeNewswire Inc.Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to TestingNASDAQ:PSNLPersonalis Inc
18/06/202417:01Business WirePersonalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution ConferenceNASDAQ:PSNLPersonalis Inc
13/06/202409:00Business WirePersonalis Provides Dial-in and Updated Date for ASCO Highlights Conference CallNASDAQ:PSNLPersonalis Inc
04/06/202417:05Business WireASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy MonitoringNASDAQ:PSNLPersonalis Inc
31/05/202410:05Business WirePersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with TempusNASDAQ:PSNLPersonalis Inc
22/05/202410:05Business WirePersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024NASDAQ:PSNLPersonalis Inc
08/05/202417:01Business WirePersonalis Reports First Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
24/04/202417:01Business WirePersonalis to Announce First Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
28/03/202417:01Business WirePersonalis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PSNLPersonalis Inc
28/03/202410:00Business WireData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:PSNLPersonalis Inc
26/03/202410:00Business WirePersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response MonitoringNASDAQ:PSNLPersonalis Inc
28/02/202418:01Business WirePersonalis Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PSNLPersonalis Inc
14/02/202418:01Business WirePersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PSNLPersonalis Inc
30/01/202411:00Business WirePersonalis and ClearNote Health Announce Partnership to Advance Epigenomic TechnologyNASDAQ:PSNLPersonalis Inc
29/01/202418:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PSNLPersonalis Inc
16/01/202411:05Business WirePersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling AssayNASDAQ:PSNLPersonalis Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PSNL

Seu Histórico Recente

NASDAQ
EPRX
Eupraxia Pharmaceuticals
TG
BWI
Brunswick
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados